Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies (mAbs) hold promise in treating Parkinson's disease (PD), although poor delivery to the brain hinders their therapeutic application. In the current study, it is demonstrated that brain‐targeted liposomes (BTL) enhance the delivery of mAbs across the blood‐brain‐barrier (BBB) and into neurons, thereby allowing the intracellular and extracellular treatment of the PD brain. BTL are decorated with transferrin to improve brain targeting through overexpressed transferrin‐receptors on the BBB during PD. BTL are loaded with SynO4, a mAb that inhibits alpha‐synuclein (AS) aggregation, a pathological hallmark of PD. It is shown that 100‐nm BTL cross human BBB models intact and are taken up by primary neurons. Within neurons, SynO4 is released from the nanoparticles and bound to its target, thereby reducing AS aggregation, and enhancing neuronal viability. In vivo, intravenous BTL administration results in a sevenfold increase in mAbs in brain cells, decreasing AS aggregation and neuroinflammation. Treatment with BTL also improve behavioral motor function and learning ability in mice, with a favorable safety profile. Accordingly, targeted nanotechnologies offer a valuable platform for drug delivery to treat brain neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Varadi, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., Yuan, D., Stroe, O., Wood, G., Laydon, A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1061 · Cited by 7,850
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
Dilliard, S. A., Cheng, Q., & Siegwart, D. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109256118 · Cited by 1,018
Overview of General and Discriminating Markers of Differential Microglia Phenotypes
Jurga, A. M., Paleczna, M., & Kuter, K. Z. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00198 · Cited by 1,000
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Vatine, G. D., Barrile, R., Workman, M. J., Sances, S., Barriga, B. K., Rahnama, M., Barthakur, S., Kasendra, M., Lucchesi, C., Kerns, J., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.05.011 · Cited by 632
Hopperton, K. E., Mohammad, D., Trépanier, M. O., Giuliano, V, & Bazinet, R. P. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.246 · Cited by 622
Amine coupling through EDC/NHS: a practical approach
Fischer, M. J. E. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-670-2_3 · Cited by 492
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Theranostic USPIO‐Loaded Microbubbles for Mediating and Monitoring Blood‐Brain Barrier Permeation
Lammers, T., Koczera, P., Fokong, S., Gremse, F., Ehling, J., Vogt, M., Pich, A., Storm, G., van Zandvoort, M., & Kiessling, F. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201401199 · Cited by 156
Signaling Pathways in Reactive Astrocytes, a Genetic Perspective
Kang, W., & Hébert, J. M. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8163-7 · Cited by 148
Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132
Glial activation in prion diseases is selectively triggered by neuronal PrPSc
Lakkaraju, A. K. K., Sorce, S., Senatore, A., Nuvolone, M., Guo, J., Schwarz, P., Moos, R., Pelczar, P., & Aguzzi, A. (2022) · Brain Pathology · doi:10.1111/bpa.13056 · Cited by 34
Research works printed but not linked: 64
- 10.1007/978-1-4613-0759-4_2 · DOI
- 10.1016/S1474-4422(07)70246-6 · DOI · Paper page
- 10.1016/j.nbd.2020.105028 · DOI · Paper page
- 10.1038/42166 · DOI · Paper page
- 10.1523/JNEUROSCI.4650-14.2015 · DOI · Paper page
- 10.4103/1673-5374.235013 · DOI · Paper page
- 10.3389/fnmol.2019.00299 · DOI · Paper page
- 10.1371/journal.pone.0019338 · DOI · Paper page
- 10.1523/JNEUROSCI.5314-13.2014 · DOI · Paper page
- 10.1016/j.nbd.2017.05.002 · DOI · Paper page
- 10.1021/acs.accounts.9b00277 · DOI · Paper page
- 10.1002/advs.202103240 · DOI
- 10.1002/advs.202301377 · DOI
- 10.1002/adhm.202100598 · DOI · Paper page
- 10.1007/s00262-006-0273-0 · DOI
- 10.3727/000000006783980946 · DOI · Paper page
- 10.1158/0008-5472.CAN-09-1157 · DOI · Paper page
- 10.1021/acsnano.9b01798 · DOI · Paper page
- 10.1038/s41563-023-01481-9 · DOI · Paper page
- 10.1021/acsnano.7b04495 · DOI · Paper page
- Betzer O., 2019, Proc. SPIE
- 10.7150/thno.41161 · DOI
- Lammers T., 2015, Adv. Funct. Mater., 2, 25
- 10.1038/s41467-023-37150-3 · DOI
- Attia S. A., 2021, Peptide Conjugation: Methods and Protocols
- 10.7150/thno.25228 · DOI · Paper page
- 10.1016/j.jconrel.2019.01.005 · DOI · Paper page
- 10.3389/fnins.2018.01019 · DOI · Paper page
- Gregoriadis G., 2010, Encyclopedia of Life Sciences
- 10.1073/pnas.1105786108 · DOI · Paper page
- 10.1021/nn305663e · DOI · Paper page
- 10.1126/sciadv.abj5435 · DOI
- 10.1002/advs.202101437 · DOI
- 10.1021/bc800233a · DOI · Paper page
- 10.1186/s12987-023-00450-3 · DOI
- 10.1006/dbio.2001.0439 · DOI · Paper page
- 10.1016/j.neuron.2019.11.028 · DOI
- 10.1021/mp800049w · DOI · Paper page
- 10.1111/j.1365-2990.1994.tb00997.x · DOI · Paper page
- 10.1007/s11095-022-03433-5 · DOI
- 10.1016/S0006-8993(96)01412-6 · DOI
- 10.1038/nrdp.2017.13 · DOI · Paper page
- 10.1186/s13024-020-00368-6 · DOI · Paper page
- 10.1016/j.redox.2021.101896 · DOI · Paper page
- 10.1038/s41531-022-00366-z · DOI
- 10.1016/S0166-2236(97)01139-9 · DOI · Paper page
- 10.1186/1756-6606-3-12 · DOI · Paper page
- 10.1016/j.nurt.2010.07.003 · DOI · Paper page
- 10.1007/s10637-017-0520-6 · DOI · Paper page
- 10.1038/nmeth.2019 · DOI · Paper page
- 10.1093/cercor/bht081 · DOI
- 10.1016/j.stemcr.2019.05.008 · DOI · Paper page
- 10.1063/5.0039366 · DOI
- 10.1038/nprot.2016.002 · DOI
- 10.1038/nmeth.1768 · DOI · Paper page
- 10.1016/j.neuron.2016.09.014 · DOI · Paper page
- 10.1093/bioinformatics/btu202 · DOI · Paper page
- 10.1038/nmeth.2089 · DOI · Paper page
- 10.7554/eLife.10032 · DOI · Paper page
- 10.1038/s41380-021-01281-0 · DOI
- 10.1073/pnas.1722677115 · DOI
- 10.1016/j.neuroscience.2013.08.021 · DOI
- 10.1016/j.expneurol.2008.03.007 · DOI
- 10.1016/j.brainresbull.2022.08.016 · DOI
Cited by
Ding, L., Kshirsagar, P., Agrawal, P., & Murry, D. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060706 · Cited by 62
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52
“25 In recent years, diverse strategies have been developed to inhibit α-syn aggregation and regulate its expression.”
He, J., Xue, W., & Li, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s560983 · Cited by 16
Pramoda, G., Verma, R. K., Kesharwani, P., & Shukla, R. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.127938 · Cited by 15
Martos, D., Lőrinczi, B., Szatmári, I., Vécsei, L., & Tanaka, M. (2025) · doi:10.20944/preprints202504.1511.v2 · Cited by 13
Metadata
- Authors
- Sela, M., Poley, M., Mora‐Raimundo, P., Kagan, S., Avital, A., Kaduri, M., Chen, G., Adir, O., Rozencweig, A., Weiss, Y., Sade, O., Leichtmann‐Bardoogo, Y., Simchi, L., Aga‐Mizrachi, S., Bell, B., Yeretz‐Peretz, Y., Or, A. Z., Choudhary, A., Rosh, I., Cordeiro, D., Cohen‐Adiv, S., Berdichevsky, Y., Odeh, A., Shklover, J., Shainsky‐Roitman, J., Schroeder, J. E., Hershkovitz, D., Hasson, P., Ashkenazi, A., Stern, S., Laviv, T., Ben‐Zvi, A., Avital, A., Ashery, U., Maoz, B. M., & Schroeder, A.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2023-10-27
- Volume
- 35
- Issue
- 51
- Pages
- e2304654-e2304654
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W4387077144
- Cited by
- 91
- References
- 19
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Israel National Institute for Health Policy Research (1R21AG074846‐01A1)
- Michael J. Fox Foundation for Parkinson's Research (MJFF‐022407)
- Teva Pharmaceutical Industries
- Phospholipid Research Center (ASC‐2018‐062/1‐1)
- Israel Science Foundation (2359/23, 2248/19, 1934/23, 2141/20, 1384/21, 1881/21)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.